Atai Life Sciences N.V. (ATAI)

NASDAQ: ATAI · IEX Real-Time Price · USD
1.970
+0.180 (10.06%)
At close: Mar 28, 2024, 4:00 PM
1.920
-0.050 (-2.54%)
After-hours: Mar 28, 2024, 7:43 PM EDT
10.06%
Market Cap 275.58M
Revenue (ttm) 314,000
Net Income (ttm) -40.22M
Shares Out 166.01M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,949,124
Open 1.800
Previous Close 1.790
Day's Range 1.800 - 2.040
52-Week Range 1.025 - 2.390
Beta 0.97
Analysts Strong Buy
Price Target 14.67 (+644.67%)
Earnings Date Mar 28, 2024

About ATAI

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 18, 2021
Employees 133
Stock Exchange NASDAQ
Ticker Symbol ATAI
Full Company Profile

Financial Performance

In 2023, ATAI's revenue was $314,000, an increase of 34.76% compared to the previous year's $233,000. Losses were -$40.22 million, -73.60% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $14.67, which is an increase of 644.67% from the latest price.

Price Target
$14.67
(644.67% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

NEW YORK and BERLIN, March 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences  (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

1 day ago - GlobeNewsWire

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect  in TRD patients, with 45% of patients in clinical remission at week 12

2 days ago - GlobeNewsWire

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

NEW YORK and BERLIN, March 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

25 days ago - GlobeNewsWire

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde...

4 weeks ago - GlobeNewsWire

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company's interim Chief Financial Officer since Oc...

7 weeks ago - GlobeNewsWire

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

NEW YORK and BERLIN, Jan. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental h...

3 months ago - GlobeNewsWire

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde...

4 months ago - GlobeNewsWire

atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde...

6 months ago - GlobeNewsWire

atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde...

6 months ago - GlobeNewsWire

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disord...

7 months ago - GlobeNewsWire

atai Life Sciences to Participate in Upcoming September Investor Conferences

NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disord...

7 months ago - GlobeNewsWire

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

NEW YORK and BERLIN, Aug. 10, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde...

8 months ago - GlobeNewsWire

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde...

8 months ago - GlobeNewsWire

FDA issues guidance on psychedelic drug clinical trials

The U.S. Food and Drug Administration on Friday issued its first draft guidance on psychedelic drug clinical trials, outlining considerations for companies investigating the drugs' potential to treat ...

Other symbols: CMPSCYBN
10 months ago - Market Watch

TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.

Blake Mycoskie, founder of the canvas-footwear phenomenon TOMS Shoes, has committed to giving $100 million to support psychedelic research and access, Mycoskie told MarketWatch in an exclusive intervi...

Other symbols: CMPSCYBNMNMD
10 months ago - Market Watch

atai Life Sciences to Participate in Upcoming June Investor Conferences

NEW YORK and BERLIN, June 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde...

10 months ago - GlobeNewsWire

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorder...

11 months ago - GlobeNewsWire

atai Life Sciences to Participate in Upcoming May Investor Conference

NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorder...

11 months ago - GlobeNewsWire

atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting

- Pharmacodynamic profile of GRX-917 indicates potential for anxiolytic activity without the significant sedative side effects associated with benzodiazepines

1 year ago - GlobeNewsWire

atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disord...

1 year ago - GlobeNewsWire

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

NEW YORK and BERLIN, March 24, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disord...

1 year ago - GlobeNewsWire

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disord...

1 year ago - GlobeNewsWire

atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disord...

1 year ago - GlobeNewsWire

The stock of psychedelics giant Atai is tumbling after a treatment failed to help patients in a trial

Atai Life Sciences' ketamine-based therapy failed to help patients with depression in a mid-stage trial.

1 year ago - Business Insider

Atai says its depression treatment failed in a mid-stage clinical trial

Shares of Atai Life Sciences NV ATAI, -2.59% tumbled about 44% in premarket trading on Friday after the company said a Phase 2a clinical trial evaluating a ketamine therapy for treatment-resistant dep...

1 year ago - Market Watch